CeleCor Completes FDA Submission for Zalunfiban, a First-Point-of-Care Antiplatelet for STEMI Heart Attacks
核心洞察
CeleCor Therapeutics (搜索) has completed its rolling New Drug Application submission to the FDA for zalunfiban (Disaggpro), an investigational subcutaneous antiplatelet therapy for STEMI (搜索) heart attacks.
The filing follows positive Phase 3 CeleBrate study results showing rapid zalunfiban treatment at first medical contact lowered the risk of severe heart damage and complications.
Zalunfiban is a novel small-molecule GPIIb/IIIa receptor (搜索) inhibitor designed for subcutaneous injection before patients reach a catheterization laboratory.
CeleCor Therapeutics (搜索) has submitted the final section of its New Drug Application (NDA) to the U.S. Food and Drug Administration for zalunfiban (Disaggpro), an investigational heart-attack drug designed for subcutaneous injection at the first point of medical contact for ST-segment elevation myocardial infarction (STEMI (搜索)), the most severe form of heart attack.
The NDA filing follows the presentation of positive Phase 3 results from the multinational CeleBrate study at the American Heart Association Scientific Sessions in November, as well as publication of the results in The New England Journal of Medicine Evidence.
Zalunfiban has FDA Fast Track status and was granted Rolling Review in January, allowing the company to submit documents and data as they became available. This regulatory pathway enables the FDA to begin its review early, creating the potential to shorten the overall review timeline.
Clinical Rationale and Mechanism of Action
STEMI (搜索) heart attacks demand urgent intervention; the priority is opening the occluded coronary artery as quickly as possible to prevent death or irreversible heart damage. Clinical outcomes depend heavily on how rapidly the blocked artery is reopened and how effectively early thrombotic complications are controlled.
Zalunfiban is a novel small-molecule inhibitor of the platelet GPIIb/IIIa receptor (搜索), specifically designed for subcutaneous injection at the first point of medical contact — before patients reach a catheterization laboratory. This approach addresses a practical gap in STEMI (搜索) care: while hospital-based intervention remains essential, the earliest phase of treatment often occurs in ambulances, emergency departments, or community settings where speed is critical. A treatment that can be administered earlier could help reduce the risk of more severe heart damage before definitive revascularization.
Phase 3 CeleBrate Study Findings
The multinational CeleBrate study found that rapid zalunfiban treatment at first medical contact lowered the risk of more severe heart damage in combination with other serious heart-attack complications. These findings support the company's strategy of targeting the earliest stage of STEMI (搜索) care rather than waiting until patients reach specialized facilities.
Commercial Preparations
CeleCor also announced the appointment of Michael Moye as Chief Commercial Officer to lead commercial strategy and operations in support of zalunfiban. Moye joins the company after holding key leadership positions at Idorsia, Shire, and Johnson & Johnson. The therapy's adoption will depend not only on regulatory approval but also on integration with emergency care protocols, hospital networks, ambulance services, and clinician confidence in early administration.
Regulatory Status
Zalunfiban remains investigational; it has not been approved for any use, and its safety and efficacy have not been established by regulators. CeleCor Therapeutics (搜索), based in Del Mar, California, was founded to improve the treatment of STEMI (搜索) heart attacks at the first point of medical contact.